{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T05:10:30Z","timestamp":1732597830405,"version":"3.28.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,25]]},"DOI":"10.7759\/cureus.74401","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T12:56:58Z","timestamp":1732539418000},"source":"Crossref","is-referenced-by-count":0,"title":["The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia"],"prefix":"10.7759","author":[{"given":"Wafaa S","family":"Sayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aws","family":"Al-Bayati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina G","family":"Elzubair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mueed","family":"Alharthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Myeloproliferative neoplasms (MPNs). (2024). Accessed. November 23, 2024: http:\/\/www.cancersupportcommunity.org\/myeloproliferative-neoplasms."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter EJ","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al.. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365:1054-61. 10.1016\/S0140-6736(05)71142-9","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine RL","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, et al.. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7:387-97. 10.1016\/j.ccr.2005.03.023","journal-title":"Cancer Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones AV","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, et al.. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005, 106:2162-8. 10.1182\/blood-2005-03-1320","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell PJ","year":"2006","unstructured":"Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006, 355:2452-66. 10.1056\/NEJMra063728","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch HC","year":"2021","unstructured":"Hasselbalch HC, Elvers M, Schafer AI. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood. 2021, 137:2152-60. 10.1182\/blood.2020008109","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00688.x","article-title":"JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status","volume":"77","author":"Heller PG","year":"2006","unstructured":"Heller PG, Lev PR, Salim JP, et al.. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol. 2006, 77:210-6. 10.1111\/j.1600-0609.2006.00688.x","journal-title":"Eur J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/BF03324948","article-title":"JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia","volume":"23","author":"Randi ML","year":"2011","unstructured":"Randi ML, Ruzzon E, Tezza F, Scapin M, Duner E, Scandellari R, Fabris F. JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia. Aging Clin Exp Res. 2011, 23:17-21. 10.1007\/BF03324948","journal-title":"Aging Clin Exp Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1179\/102453309X12473408860226","article-title":"Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders","volume":"14","author":"Basquiera AL","year":"2009","unstructured":"Basquiera AL, Soria NW, Ryser R, et al.. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology. 2009, 14:323-30. 10.1179\/102453309X12473408860226","journal-title":"Hematology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1556\/OH.2011.29226","article-title":"[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]","volume":"152","author":"Iv\u00e1nyi JL","year":"2011","unstructured":"Iv\u00e1nyi JL, Marton E, Plander M. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]. Orv Hetil. 2011, 152:1795-803. 10.1556\/OH.2011.29226","journal-title":"Orv Hetil"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung B","year":"2006","unstructured":"Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006, 132:244-5. 10.1111\/j.1365-2141.2005.05858.x","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi A","year":"2006","unstructured":"Tefferi A, Lasho TL, Schwager SM, et al.. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006, 106:631-5. 10.1002\/cncr.21645","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli E","year":"2005","unstructured":"Antonioli E, Guglielmelli P, Pancrazzi A, et al.. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005, 19:1847-9. 10.1038\/sj.leu.2403902","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0519-3","article-title":"Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease","volume":"51","author":"Klarin D","year":"2019","unstructured":"Klarin D, Busenkell E, Judy R, et al.. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet. 2019, 51:1574-9. 10.1038\/s41588-019-0519-3","journal-title":"Nat Genet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj AP","year":"2005","unstructured":"Wolanskyj AP, Lasho TL, Schwager SM, et al.. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005, 131:208-13. 10.1111\/j.1365-2141.2005.05764.x","journal-title":"Br J Haematol"},{"key":"ref17","article-title":"Screening for inherited thrombophilia: indications and therapeutic implications","volume":"87","author":"De Stefano V","year":"2002","unstructured":"De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002, 87:1095-108.","journal-title":"Haematologica"},{"key":"ref18","article-title":"Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia","volume":"80","author":"De Stefano V","year":"1995","unstructured":"De Stefano V, Leone G. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica. 1995, 80:344-56.","journal-title":"Haematologica"},{"key":"ref19","article-title":"Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with myeloproliferative disorders","volume":"10","author":"Tevet M","year":"2015","unstructured":"Tevet M, Ionescu R, Dragan C, Lupu AR. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with myeloproliferative disorders. Maedica (Bucur). 2015, 10:27-32.","journal-title":"Maedica (Bucur)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.s.032","article-title":"Molecular and genetic bases of myeloproliferative disorders: questions and perspectives","volume":"9","author":"Plo I","year":"2009","unstructured":"Plo I, Vainchenker W. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. Clin Lymphoma Myeloma. 2009, 9:S329-39. 10.3816\/CLM.2009.s.032","journal-title":"Clin Lymphoma Myeloma"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10153","article-title":"Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia","volume":"71","author":"Ruggeri M","year":"2002","unstructured":"Ruggeri M, Gisslinger H, Tosetto A, et al.. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 2002, 71:1-6. 10.1002\/ajh.10153","journal-title":"Am J Hematol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1515\/tjb-2018-0054","article-title":"Evaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from eastern Anatolia","volume":"44","author":"Gulbay G","year":"2019","unstructured":"Gulbay G, Yesilada E, Erkurt M, Bag H, Kuku I, Kaya E. Evaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from eastern Anatolia. Turk J Biochem. 2019, 44:492-8. 10.1515\/tjb-2018-0054","journal-title":"Turk J Biochem"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13010163","article-title":"Molecular genetics of thrombotic myeloproliferative neoplasms: implications in precision oncology","volume":"13","author":"Chia YC","year":"2023","unstructured":"Chia YC, Siti Asmaa MJ, Ramli M, Woon PY, Johan MF, Hassan R, Islam MA. Molecular genetics of thrombotic myeloproliferative neoplasms: implications in precision oncology. Diagnostics (Basel). 2023, 13:163. 10.3390\/diagnostics13010163","journal-title":"Diagnostics (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia","volume":"33","author":"Dahabreh IJ","year":"2009","unstructured":"Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009, 33:67-73. 10.1016\/j.leukres.2008.06.006","journal-title":"Leuk Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13869","article-title":"Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia","volume":"94","author":"De Stefano V","year":"2009","unstructured":"De Stefano V, Za T, Rossi E, et al.. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009, 94:733-7. 10.3324\/haematol.13869","journal-title":"Haematologica"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V112.11.5257.5257","article-title":"JAK2 mutation and additional thrombophilic markers predispose to thrombosis in myeloproliferative diseases with thrombocythemia","volume":"112","author":"Penka M","year":"2008","unstructured":"Penka M, Schwarz J, Doubek M. JAK2 mutation and additional thrombophilic markers predispose to thrombosis in myeloproliferative diseases with thrombocythemia. Blood. 2008, 112:5257. 10.1182\/blood.V112.11.5257.5257","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio A","year":"2008","unstructured":"Carobbio A, Antonioli E, Guglielmelli P, et al.. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008, 26:2732-6. 10.1200\/JCO.2007.15.3569","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/317392-the-association-between-janus-kinase-2-and-factor-v-leiden-mutations-and-thrombotic-complications-in-patients-with-myeloproliferative-disorders-a-study-from-saudi-arabia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T12:57:01Z","timestamp":1732539421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/317392-the-association-between-janus-kinase-2-and-factor-v-leiden-mutations-and-thrombotic-complications-in-patients-with-myeloproliferative-disorders-a-study-from-saudi-arabia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.74401","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}